ASCENT-03: Trodelvy demonstrates highly statistically significant & clinically meaningful improvement in progression free survival in patients with first-line metastatic TNBC who are not candidates for checkpoint inhibitors

CAR-T Digest - August 2020

Weekly Digest - May 2025

23 May 2025: ASCENT-03: Trodelvy demonstrates highly statistically significant & clinically meaningful improvement in progression free survival in patients with first-line metastatic TNBC who are not candidates for checkpoint inhibitors

The Phase 3 ASCENT-03 study showed that Trodelvy significantly improved progression-free survival (PFS) compared to chemotherapy in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are ineligible for checkpoint inhibitors
Trodelvy’s safety profile in ASCENT-03 was consistent with previous studies, with no new safety concerns, and overall survival data is still being collected. This is the first clinically meaningful advancement in over 20 years for this patient group, addressing a critical unmet need in an aggressive cancer type
Trodelvy remains the only Trop-2-directed antibody-drug conjugate with demonstrated survival benefits in both mTNBC and HR+/HER2- mBC, supported by multiple Phase 3 trials and international clinical use